LINC00467: A Potential Drug Target and Biomarker (G84791)

Target Name: LINC00467

NCBI ID: G84791

LINC00467

Other Name(s): ASAP | RP11-318L16.3 | C1orf97 | long intergenic non-protein coding RNA 467 | Long intergenic non-protein coding RNA 467

LINC00467: A Potential Drug Target and Biomarker

LINC00467 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of gene expression of the myeloid-specific transcription factor N-porin (NCOI), which is involved in the development of myeloid cells and functions. NCOI is a transcription factor involved in regulating the fate of hematopoietic stem cells to myeloid cells. The gene expression levels of NCOIs play an important role in a variety of diseases, including leukemia, osteomyelitis, and defects in immune system development.

As a non-coding RNA molecule, LINC00467's function and mechanism of action in cells are not yet fully understood. However, studies have shown that LINC00467 plays an important role in the development and proliferation of myeloid cells. The combination of LINC00467 and NCOI will inhibit the activity of NCOI, thus inhibiting the promotion effect of NCOI on gene expression. In addition, LINC00467 can also bind to specific sequences on DNA, thereby participating in the process of gene transcription and RNA splicing.

As a drug target, LINC00467 has potential application value in the treatment of leukemia. Leukemia is a type of hematological malignant tumor caused by abnormal proliferation of hematopoietic stem cells. It is one of the diseases that seriously threatens human health. Currently, chemotherapy and radiotherapy are the main means of treating leukemia, but the therapeutic effect is still poor. Therefore, finding new therapeutic targets is of great clinical significance.

LINC00467 has attracted widespread attention from scientists as a potential drug target. The researchers studied the regulatory mechanism of LINC00467 gene expression levels and explored the role of LINC00467 in the treatment of leukemia. They found that the expression level of LINC00467 was closely related to the prognosis and therapeutic effect of leukemia. In addition, the researchers also found that the expression level of LINC00467 is related to certain immune system functions, which provides new ideas for studying the role of LINC00467 in immune system regulation.

In addition to being a drug target, LINC00467 also has potential as a biomarker. Since the mechanism of action of LINC00467 in various diseases is still unclear, by studying the expression levels of LINC00467, we can better understand the development and progression of the disease. In addition, the expression level of LINC00467 can also be used as a biomarker to evaluate the effect of treatment, providing clinicians with a more accurate basis for disease prognosis and treatment evaluation.

In conclusion, LINC00467, as a non-coding RNA molecule, has potential as a drug target and biomarker. Further research on the molecular mechanism and mechanism of action of LINC00467 can provide important theoretical basis and experimental support for the development of new treatments and biomarkers.

Protein Name: Long Intergenic Non-protein Coding RNA 467

The "LINC00467 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00467 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets